Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Cell Medica Announces Senior Management Appointments

Published: Friday, March 08, 2013
Last Updated: Thursday, March 07, 2013
Bookmark and Share
Key appointments to Cell Medica's senior executive team.

Cell Medica has announced key appointments to its senior executive team.

The strengthened management team will enable Cell Medica to broaden its product development activities, particularly in the US, and will support further international growth.

Dr. Kurt Gunter joins Cell Medica as Chief Medical Officer and will have a senior role in managing the clinical and regulatory aspects of the Company’s therapeutic products with a focus on the cancer immunotherapy program.

As Chief Financial Officer, Jeff Hammel will be responsible for Cell Medica’s global financial and business management systems to drive the continued growth of Cell Medica’s commercial operations in both Europe and the US.

Ross Durland, PhD, has joined as Senior Vice President Development with global responsibility for product development activities.

Ross will focus on the Company’s pipeline strategy while also assisting in setting up the manufacturing operations in the US.

The new members of the executive team will be based in Cell Medica’s recently established US office in Houston, Texas and will have global responsibility for their respective functions.

Also joining the Houston office are Cynthia Molina, Senior Director Regulatory Affairs and Shannon Inman, Director Clinical Operations, each with regional responsibility for the US.

Gregg Sando, CEO of Cell Medica, commented, “Expanding our management team with such experienced biotech professionals is a crucial step as we extend our operations to the US market. For Cell Medica, this represents an important growth milestone in our strategy to build an industry leader in cellular therapeutics on a global basis.”

Dr. Kurt Gunter, Chief Medical Officer
Kurt has devoted his career to the development of cell and gene therapies and brings significant commercial experience to Cell Medica from his previous positions at Hospira, ViaCell and Transkaryotic Therapies.

As current President of the International Society for Cellular Therapy (ISCT), Kurt plays a worldwide leadership role in promoting the understanding of the clinical, regulatory, manufacturing and marketing requirements for the successful development of cell and gene therapies.

Prior to his biotech career, he worked at the U.S. Food and Drug Administration as a Medical Officer and was appointed Acting Deputy Director of the Division of Cell and Gene Therapy within the Center for Biologics Evaluation and Research (CBER).

Jeff Hammel, Chief Financial Officer
Jeff joins Cell Medica with over 17 years of broad financial and operational experience in the healthcare industry. In his previous role as Chief Financial Officer for the largest operating division of Orthofix International NV, Jeff managed the global financial operations for a medical technology business with $300 million revenues across all major international markets.

Jeff played an active role in providing financial and analytical support to manage strategic and operational goals. He was also a key member of the integration team for a significant acquisition.

Prior to Orthofix, Jeff spent eight years at the head office of Eli Lilly & Company where his final position was US Controller for the $7.0 billion US pharmaceutical division.

Ross Durland, Senior Vice President Development
Ross has over 20 years of experience in the development of highly innovative therapeutic products and technologies. He gained significant experience with cell-based therapeutics while at Valentis (formerly GeneMedicine; The Woodlands, TX) where he rose to Senior Director Preclinical Development and led multi-site, multidisciplinary product development teams advancing two new gene therapy products from animal proof-of-concept to human clinical testing.

During his time at Valentis, Ross also participated in developing five additional clinical stage products, and led the company’s manufacturing and quality control functions in manufacturing products for preclinical and clinical testing.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cell Medica Secures £17 Million Equity Investment
Investment to establish US operations and fund cell therapy development.
Monday, August 06, 2012
Scientific News
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.
A New Single-Molecule Tool to Observe Enzymes at Work
A team of scientists at the University of Washington and the biotechnology company Illumina have created an innovative tool to directly detect the delicate, single-molecule interactions between DNA and enzymatic proteins.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos